Xeris Biopharma to Participate at the Jefferies Healthcare Conference
01 6월 2023 - 8:00PM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that members of its senior management
will participate in a fireside chat at the Jefferies Healthcare
Conference on Thursday, June 8 at 10:30am Eastern Time.
A live webcast of the event will be available on the 'Events
& Presentations' section of Xeris’ Investor Relations website
at https://xerispharma.com/investor-relations or https://wsw.com/webcast/jeff281/xers/1879020.
A replay of the webcast will be available for 60 days.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™, to support long-term product development and commercial
success.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn or
Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230601005342/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Xeris Biopharma (NASDAQ:XERS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024